CD8A and neoplasm: Although further evaluation among a larger patient population is needed, the initial observations with ELI-002 2P suggest that vaccine-induced T cell reactivities and anti-tumor responses were not limited to patients with known mKRAS-peptide binding HLA class I. Specifically, class I HLA alleles (A*02:01, A*03:01, A*11:01, B*07:02 and C*08:02), previously reported to restrict CD8+ T cell responses to mKRAS G12D or G12R mutations, were not required for T cell response, and this result was not explained by induction of CD4+ rather than CD8+ responses.